This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- There are no systematically collected data to define the post-injection observation time of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for subcutaneous (SC) use. Clinical judgment should be exercised when considering observation times after RYBREVANT FASPRO injection.
- RYBREVANT FASPRO for SC administration is a coformulation of amivantamab with recombinant human hyaluronidase PH20 (rHuPH20).1
- LAZCLUZE (lazertinib) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).2
- PALOMA-3 (NCT05388669) is phase 3, open-label, international, randomized study evaluating the noninferiority of pharmacokinetics, efficacy, and safety of RYBREVANT FASPRO plus LAZCLUZE (n=206) vs RYBREVANT plus LAZCLUZE (n=212) in patients with EGFR-mutated (Exon 19 deletion [Exon19del] or Exon 21 L858R) locally advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression on or after osimertinib and platinum-based chemotherapy (N=418).1,3
- Infusion-related reactions (IRRs) cover a range of symptoms or systemic reactions that can occur in response to the infusion or administration of amivantamab, such as chills, dyspnea, chest discomfort, fever, and flushing. In the PALOMA-3 study, where patients were randomized to receive either RYBREVANT FASPRO or RYBREVANT, these reactions were consistently recorded as IRRs to maintain sponsor blinding. IRRs reported in the RYBREVANT FASPRO plus LAZCLUZE treatment group were considered as a systemic reaction related to SC administration.4
- The median time to onset of first IRR (calculated as the time from the most recent amivantamab administration to the start of IRR) in the RYBREVANT FASPRO plus LAZCLUZE treatment group (n=206) was 105 minutes (range, 0-2056).5
- PALOMA-2 (NCT05498428) is an ongoing, phase 2, open-label, international, parallel-cohort study evaluating the efficacy, safety, and pharmacokinetics of first-line RYBREVANT FASPRO with chemotherapy and/or LAZCLUZE combination therapy in patients with locally advanced or metastatic EGFR-mutated NSCLC (N=520).6,7
- As amivantamab was administered SC in the PALOMA-2 study, the term administration-related reaction (ARR) is used to describe the systemic reactions associated with SC administration, such as fever, chills, rigors, bronchospasm, headache, rash, pruritus, arthralgia, and hypo- or hypertension.8
- The median onset time for administration-related reactions (ARRs; defined as the start of ARR minus the start of the last injection prior to this event) following RYBREVANT FASPRO injection in the RYBREVANT FASPRO plus LAZCLUZE treatment group (n=125) was 2.3 hours (range, 0.3-7.2).6
- OrigAMI-4 (NCT06385080) is an ongoing, phase 1b/2, nonrandomized, open-label, multiarm, multicenter study evaluating the efficacy and safety of RYBREVANT FASPRO as monotherapy or in combination with standard-of-care therapies in patients with head and neck squamous cell carcinoma (HNSCC). Cohort 1 (n=102) evaluated RYBREVANT FASPRO monotherapy administered every 3 weeks in previously treated recurrent or metastatic HNSCC.9
- The median time to onset of ARRs (defined as the start of ARR minus the start of the last infusion prior to this event) following RYBREVANT FASPRO injection in patients who received RYBREVANT FASPRO monotherapy (cohort 1, n=102) was 134 minutes (range, 12-3205).10
- The median time to onset of ARRs at first injection (defined as on or after Cycle 1 Day 1 infusion start but before Cycle 1 Day 8 infusion start) following RYBREVANT FASPRO injection in patients who received RYBREVANT FASPRO monotherapy (cohort 1, n=102) was 122 minutes (range, 12-3205).10
- The protocols for the PALOMA-3 and PALOMA-2 studies required patients randomized to the RYBREVANT FASPRO plus LAZCLUZE treatment group to be observed for at least 4 hours after the end of SC administration on Cycle 1 Day 1 only.11,12
- The protocol for the OrigAMI-4 study required patients receiving RYBREVANT FASPRO injection to be observed for at least 4 hours after the end of SC administration on Cycle 1 Day 1 only.13
Literature Search
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 03 November 2026. The information included in this response is limited to relevant data from the PALOMA-3, PALOMA-2, and OrigAMI-4 studies.
| 1 | Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. 2024;42(30):3593-3605. |
| 2 | Cho BC, Felip E, Hayashi H, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022;18(6):639-647. |
| 3 | Janssen Research & Development, LLC. A phase 3, open-label, randomized study of lazertinib with subcutaneous amivantamab compared with intravenous amivantamab in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer after progression on osimertinib and chemotherapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 November 3]. Available from: https://clinicaltrials.gov/study/NCT05388669 NLM Identifier: NCT05388669. |
| 4 | Data on File. Amivantamab. Clinical Study Report 61186372NSC3004. Janssen Research & Development, LLC. EDMS-RIM-1232939; 2024. |
| 5 | Data on File. Amivantamab. Table TSFAE01AWP: Summary of Treatment Emergent Adverse Events required for Warning & Precautions; All Treated Analysis Set (Study-61186372NSC3004). Janssen Research & Development, LLC; 2025. |
| 6 | Lim SM, Tan JL, Dias JM, et al. Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC): interim results from the phase 2 PALOMA-2 study. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2024; Chicago, IL. |
| 7 | Janssen Research & Development, LLC. A phase 2, open-label, parallel cohort study of subcutaneous amivantamab in multiple regimens in patients with advanced or metastatic solid tumors including EGFR-mutated non-small cell lung cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 November 3]. Available from: https://clinicaltrials.gov/study/NCT05498428 NLM Identifier: NCT05498428. |
| 8 | Data on File. Amivantamab. Clinical Study Report 61186372NSC2002. Janssen Research & Development, LLC. EDMS-RIM-1438447; 2025. |
| 9 | Burtness B, Rosenberg AJ, Calderon B, et al. Amivantamab in recurrent/metastatic head and neck squamous cell cancer after checkpoint inhibitor and chemotherapy: pivotal results from the phase Ib/II OrigAMI-4 study. J Clin Oncol. 2026;44(24):2271-2277. |
| 10 | Data on File. Amivantamab SC. OrigAMI-4 Cohort 1 Primary Analysis Clinical Study Report. Janssen Research & Development, LLC. EDMS-RIM-1725095; 2026. |
| 11 | Leighl NB, Akamatsu H, Lim SM, et al. Clinical Protocol for: Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. 2024;42(30):3593-3605. |
| 12 | Data on File. Amivantamab and Lazertinib. PALOMA-2 Clinical Protocol. Janssen Research & Development, LLC. EDMS-RIM-652953; 2026. |
| 13 | Burtness B, Rosenberg AJ, Calderon B, et al. Clinical Protocol for: Amivantamab in recurrent/metastatic head and neck squamous cell cancer after checkpoint inhibitor and chemotherapy: pivotal results from the phase Ib/II OrigAMI-4 study. J Clin Oncol. 2026;44(24):2271-2277. |